P/E ratio for Abeona Therapeutics (ABEO)
P/E ratio as of May 2024 (TTM): -1.46
According to Abeona Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.46493. At the end of 2022 the company had a P/E ratio of -0.4595.
P/E ratio history for Abeona Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.4595 | 14.76% |
| 2021 | -0.4004 | -76.79% |
| 2020 | -1.73 | -19.8% |
| 2019 | -2.15 | -64.45% |
| 2018 | -6.05 | -74.8% |
| 2017 | -24.0 | 216.9% |
| 2016 | -7.58 | 15.03% |
| 2015 | -6.59 | 5648.72% |
| 2014 | -0.1146 | -102.92% |
| 2013 | 3.92 | -949.01% |
| 2012 | -0.4615 | -92.95% |
| 2011 | -6.55 | 50.44% |
| 2010 | -4.35 | 114.24% |
| 2009 | -2.03 | 626.19% |
| 2008 | -0.2797 | -11.11% |
| 2007 | -0.3146 | -59.04% |
| 2006 | -0.7680 | -84.34% |
| 2005 | -4.91 | -4.94% |
| 2004 | -5.16 | -47.61% |
| 2003 | -9.85 | 372.78% |
| 2002 | -2.08 | -77.95% |
| 2001 | -9.45 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Merck MRK | 71.1 | -4,954.55% | 🇺🇸 USA |
 Taro Pharmaceutical TARO | 69.3 | -4,831.39% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.